TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03981016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: * blood samples collected at different times : Before surgery and during the post-operative visit and~* frozen tumor samples and / or paraffin samples at the time of surgery and- paraffin around tumor samples at the time of surgery
Study: NCT00545623

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Response
Description: listening to CDs with verbal instructions of techniques to elicit relaxation response

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Response
Description: listening to CDs with verbal instructions of techniques to elicit relaxation response

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham acupuncture
Description: sham acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
Study: NCT05419167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP-COVID
Description: The program is offered by two facilitators to groups of three to six women, online in a synchronous mode. The intervention is divided into two phases, each including three sessions. The first 3 sessions aim to explore how the participants feel, to better understand what makes them feel this way, to allow them to exchange with other people who are going through similar experiences, and to support the ability to manage stress and more unpleasant emotions. The following three sessions aim to enable participants to refocus on their experience of pregnancy and motherhood by giving them the opportunity to reflect upon how they wish to be as mothers, upon how their personal history influences their experience of pregnancy and motherhood, upon the moments that, as mothers, might be the most pleasant and those that will require more adaptations, and upon identifying the needs they have or expect to have after childbirth as well as the resources available to them to meet these needs.
Study: NCT01381926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: exenatide 5mcg sq twice daily for one month and exenatide 10mcg twice daily for month 2. The 3rd month is a washout period. Month 4 and 5 saline placebo is given as 5mcg and 10mcg respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Description: exenatide 5mcg sq twice daily for one month and exenatide 10mcg twice daily for month 2. The 3rd month is a washout period. Month 4 and 5 saline placebo is given as 5mcg and 10mcg respectively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Month 1 and 2 saline placebo is given as a low and high dose respectively. The 3rd month is a washout period. Month 4 exenatide 5mcg sq twice daily and for month 5 exenatide 10mcg twice daily is administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Month 1 and 2 saline placebo is given as a low and high dose respectively. The 3rd month is a washout period. Month 4 exenatide 5mcg sq twice daily and for month 5 exenatide 10mcg twice daily is administered.
Study: NCT00245180

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Exercise
Study: NCT03889353

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI sessions
Description: up to 3 test sessions (D-30) to eliminate BCI illiteracy, then 10 rehabilitation sessions of 90 minutes (D1-D5 and D8-D12) - Session content : Guided training - Control of an avatar (VR, first person view) of the affected limb by motor mental imagery decoded by a brain computer interface.
Study: NCT00963976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: labetalol/hydralazine/enalapril
Description: Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: labetalol/hydralazine/enalapril
Description: Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
Study: NCT00707967

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's candidate Mycobacterium tuberculosis vaccine 692342
Description: Intramuscular injection, 2 doses at 0, 1 month

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control vaccine with the adjuvant system.
Description: Intramuscular injection, 2 doses at 0, 1 month

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control vaccine with physiological saline
Description: Intramuscular injection, 2 doses at 0, 1 month
Study: NCT04380376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Inhalations with low doses of Melphalan for 7-10 consequent days

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: the patients will receive only SOC (standard of care) treatment
Study: NCT02938117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cycling exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cycling exercises
Study: NCT03248648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: patient receive 0.5mg/dose neostigmine +18ml 0.25%bupivacaine in a total volume of 20 ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: patient receive 0.5 mg/kg ketamine+18ml 0.25%bupivacaine in a total volume of 20 ml.
Study: NCT00588146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alpha2b
Description: Weekly subcutaneous injection of 1 microgram/kg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alpha2b
Description: Weekly subcutaneous injection of 1 microgram/kg/week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Standard care
Study: NCT02217111

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adventures in Voice: Pediatric Voice Therapy
Study: NCT00678847

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: KFH NOVO (inactive) + SCT
Description: inactive device (placebo) 2 x 1hour/day for total period of 8 weeks + standardized conventional therapy (SCT)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KFH Novo (BEST) + SCT
Description: 2 x 1 hour/day bio-electrical stimulation (BEST) for total period for total period of 8 weeks in combination with standardized conventional therapy (SCT)
Study: NCT01701544

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NBM DBS
Description: Deep Brain Stimulation targeting the Nucleus Basalis of Meynert

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NBM DBS
Description: Deep Brain Stimulation targeting the Nucleus Basalis of Meynert
Study: NCT00667992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide HFA
Description: standard daily inhaled dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide HFA
Description: standard daily inhaled dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide CFC
Description: standard daily inhaled dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide CFC
Description: standard daily inhaled dose
Study: NCT02915172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Phase 1 Dose Escalation: Starting dose of Lenvatinib 10 mg by mouth once daily of a 21 day cycle.~Phase 2 Dose Expansion: Starting dose of Lenvatinib is maximum tolerated dose from Phase 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Phase 1 Dose Escalation and Phase 2 Dose Expansion: Capecitabine 1000 mg/m2 twice daily by mouth on Days 1 - 14 of a 21 day cycle.
Study: NCT04553614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based HIIT
Description: Home-based HIIT uses body-weight equipment free exercises. Participants complete all exercise in their own own at a time of their choosing. This potentially removes many of the barriers preventing at risk-individuals from engaging with the current exercise referral scheme, such as cost, time or intimidating gym environment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual exercise referral scheme procedure.
Study: NCT01258478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Three weeks of outpatient, intensive physical rehabilitation before lung resection surgery.
Study: NCT01021618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Regadenoson (0.4mg/5 mL) injection during symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Symptom-limited exercise
Description: Dipyridamole (0.56 mg/kg) over 4 minutes followed by symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
Study: NCT00196157

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: linear anatomically oriented ablations
Description: linear lesions to ablate persistent atrial fibrillation
Study: NCT01258478

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: Usual care
Study: NCT02202798

Intervention type: DEVICE
Intervention: Syringe device
Study: NCT00366782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rB/HPIV3
Description: Live attenuated rB/HPIV3 vaccine given at a dose of 10\^6 TCID50

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rB/HPIV3
Description: Live attenuated rB/HPIV3 vaccine given at a dose of 10\^6 TCID50

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rB/HPIV3
Description: Live attenuated rB/HPIV3 vaccine given at a dose of 10\^6 TCID50

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rB/HPIV3
Description: Live attenuated rB/HPIV3 vaccine given at a dose of 10\^5 TCID50

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for rB/HPIV3 vaccine
Study: NCT01418911

Intervention type: OTHER
Intervention: questionnaire
Description: questionnaire only
Study: NCT02408731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMZ-2010 (Centhaquin)
Description: As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMZ-2010 (Centhaquin)
Description: As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMZ-2010 (Centhaquin)
Description: As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMZ-2010 (Centhaquin)
Description: As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMZ-2010 (Centhaquin)
Description: As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMZ-2010 (Centhaquin)
Description: As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.
Study: NCT03958188

Intervention type: OTHER
Intervention: Standardized computerized tomography (CT) reading grid for preoperative planning
Description: Using the standardized reading grid, the following data will be collected:~* Small Intestine: tumor, parietal thickening, occlusive syndrome, proximity of the tumor with the ileocecal valve.~* Mesenteric mass: presence, size, shape, contours, calcifications, enhancement, superior mesenteric arterial invasion and number of non-invaded arterial arteries.~* Mesentery: moniliform venous dilatations, combed appearance.~* Duodenal invasion.~* Lymphadenopathies (Mesenteric, Right mesocolic and Retropancreatic): presence, size, shape, enhancement~The anonymized CT exam will be reviewed by an expert radiologist and a radiology resident from imaging department of the Hospital.
Study: NCT03559283

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Walking and Record Cortical Activity
Description: The cortical activity of each patient is recorded by NIRS under the following conditions:~* Simple task : The patient walks on an electronic walking track (GAITRite system) over 10 meters. The data collected are the spatio-temporal parameters of walking.~* Cognitive task alone : two conditions of the n-back test (1-back and 2-back) to study neural activities related to working memory. The duration of realization will be 30 seconds by condition and we retain the number of errors realized.~* Double Task : Achievement of the motor task (10-meter walk) is performed at the same time as a weak cognitive task (1-back) and a high cognitive task (2-back). The spatio-temporal parameters and the number of errors are collected by the observer.
Study: NCT02403050

Intervention type: DEVICE
Intervention: Fiducial markers
Description: 2 fiducial markers (Visicoils) to be placed in the tumor area
Study: NCT03925337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer Aided Diagnostic Software
Description: The research software is deep learning algorithm used to aid in the detection of polyps (abnormal tissue growths in the wall of the colon and adenomas (pre-cancerous growths) during colonoscopy. In its current form, the automatic polyp detection system is installed on a computer system unit that utilizes an an operating system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer Aided Diagnostic Software
Description: The research software is deep learning algorithm used to aid in the detection of polyps (abnormal tissue growths in the wall of the colon and adenomas (pre-cancerous growths) during colonoscopy. In its current form, the automatic polyp detection system is installed on a computer system unit that utilizes an an operating system.
Study: NCT04260997

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus gasseri BNR17™ capsule
Description: Once per day (QD), 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Once per day (QD), 12 weeks
Study: NCT04394702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One Shape Single-file rotary system
Description: rotational single file system used for mechanical debridement of root canals

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual stainless steel K-file
Description: sequential manual filing with stainless steel K-files
Study: NCT04235426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.
Description: 30 patients received conventional medical treatment (NSAIDs, diclofenac 150 mg/day for 2 weeks and 1500 g vitamin B 12 per day for 6 weeks) and hand support.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 30 patients went to surgical procedure
Description: 30 patients went to surgical RELEASE OF TRANSVERSE VOLAR LIGAMENT.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injection
Description: Thirty patients were injected in the carpal tunnel with a of single ultrasound-guided Platelet Rich Plasma (1-2 ml) injections treatments
Study: NCT02608385

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: Patients will receive 3 or 5 doses of SBRT to the chosen metastases.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: Patients will receive 3 or 5 doses of SBRT to the chosen metastases.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Description: Patients will receive 3 or 5 doses of SBRT to the chosen metastases.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (200 mg) given every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (200 mg) given every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab (200 mg) given every 3 weeks.
Study: NCT03981146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 60 Minute IV Infusion
Study: NCT03335813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoesophageal Brachytherapy
Description: Balloon repositioning, multichannel brachytherapy applicator which has 6 channels instead of 3-tubes which will be used to deliver localized radiation
Study: NCT04153474

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: large-bore nephrostomy tube (LBNT)
Description: large-bore 22 french nephrostomy tube (LBNT)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: small-bore nephrostomy tube (SBNT)
Description: small-bore 14 french nephrostomy tube (SBNT)
Study: NCT01137487

Intervention type: PROCEDURE
Group type: OTHER
Intervention: monitoring of residual gastric volume
Description: measurements of residual gastric volume every six hours in patients receiving early enteral feeding and mechanical ventilation

Intervention type: PROCEDURE
Group type: OTHER
Intervention: not monitoring of residual gastric volume
Description: no measurements of residual gastric volume
Study: NCT01747096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68-Ga-DOTANOC
Study: NCT03512353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be taken orally or by IV infusion at a dose of 20 mg once-daily on days 1, 2, 8, 9, 15, 16, 22, and 23 of cycles 1-6, and at a dose 40 mg once-daily on days 1, 8, 15 of cycles 7-12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered at 20 mg/m² on days 1 and 2 of the first cycle. After that, carfilzomib will be administered at 56 mg/m² on days 8, 9, 15, and 16 of the first cycle, and then on days 1, 2, 8, 9, 15, and 16 on each 28-day cycle for the cycles 2 through 6. Starting with cycle 7 through cycle 12, carfilzomib will be administered at 70 mg/m² on days 1, 8, and 15 of each 28-day cycle. All
Study: NCT01085708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: 10 mg normal tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Type 1 granule containing rabeprazole 10 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabeprazole
Description: Type 2 granules containing rabeprazole 10 mg
Study: NCT00196157

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: focal electrophysiological oriented ablations
Description: focal electrophysiologically guided ablations to treat persistent atrial fibrillation
Study: NCT01085708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabeprazole
Description: Type 3 granules containing rabeprazole 10 mg
Study: NCT03534167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TODAY! App and Coaching
Description: The TODAY! app uses the skill building structure of Cognitive Behavior Therapy (CBT). The intervention will be divided into modules, each devoted to a particular skill. Skills addressed within the intervention include increasing social support, engaging in goal-driven behaviors and reducing mood-driven (i.e., avoidance) behaviors, seeking out positive activities, replacing cognitive distortions with more adaptive thinking styles, improving problem-solving skills, reducing avoidance patterns, and increasing alternate coping strategies. The intervention will be supplemented with brief human contact in the form of a motivational coach. The Coach will be trained on the Motivational Interviewing principles upon which the coaching protocol is based.
Study: NCT03464032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCD-135
Description: Monoclonal anti-PD-L1 antibody
Study: NCT00818155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate SR
Description: desvenlafaxine succinate SR

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00863681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (BAY63-2521)
Description: BAY63-2521: 1mg tid -2.5 mg tid oral until end of study
Study: NCT03031496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets)
Description: GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets) are cream-colored, circular, flat faced uncoated tablets with beveled edges having break line on one side and BD embossed on the other side.
Study: NCT00526448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 2000 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: 1000-1200 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a 180 mcg/week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a 180 mcg/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetin beta
Description: epoetin beta 450 UI/week
Study: NCT04058639

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: custom felt relief
Description: Felt is adjusted to the wound by cutting it in different ways and layers once every week

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard relief treatment
Description: Felt in the shape of a letter U is put around the wound once every week.
Study: NCT01673581

Intervention type: OTHER
Intervention: Survey